HPV in Blood Samples From Cervical Cancer Patients.

Status Completed

Clinical Trial Summary

By means of digital droplet PCR (ddPCR), this study examines blood samples from patients newly diagnosed with cervical cancer to investigate whether it is possible to measure the presence and amount of HPV DNA in these blood samples. The first blood sample is taken at time of diagnosis, and follow-up blood samples are collected during treatment- and follow-up visits. We expect to find a correlation between the disease stage and the viral load and also a decline in viral load after treatment. Furthermore, we hope that this method may serve as a way of detecting disease recurrence earlier than what is possible today.

Clinical Trial Description

This study hypothesises that in patients with HPV-related cervical cancer, HPV DNA may be released into the bloodstream from tumor cells. These fragments of HPV DNA shed by tumor may therefore be measured in blood samples from the patients. By using the same setting as for real-time PCR with PCR primers and probes for fluorescence detection, the study uses digital droplet PCR (ddPCR), a method based on dilution and partitioning of the blood sample in many reaction chambers or droplets, to measure absolute quantities of HPV DNA fragments in blood samples from women with different stages of cervical cancer. Patients are recruited at the time of diagnosis, where a baseline blood sample is collected. Follow-up blood samples are collected during treatment and at follow-up visits up to two years after the diagnosis. We expect the HPV DNA load to decrease after treatment, and if an increase in viral load is detected during follow-up, we expect this to be an early sign of a disease recurrence. The method may therefore become an effective monitoring tool in these patients in terms of detecting a ongoing disease recurrence, which gives us the chance to intervene and treat these patients before the disease becomes too disseminated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03749720
Study type	Interventional
Source	University of Aarhus
Contact
Status	Completed
Phase	N/A
Start date	June 15, 2018
Completion date	October 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04001413` - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients	Phase 2
Active, not recruiting	`NCT03260023` - Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers	Phase 1/Phase 2
Recruiting	`NCT04857528` - Detecting HPV DNA in Anal and Cervical Cancers
Recruiting	`NCT05247853` - HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Completed	`NCT03033550` - Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings	N/A
Recruiting	`NCT05973487` - A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors	Phase 1
Terminated	`NCT05061940` - This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Recruiting	`NCT03475953` - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05686226` - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers	Phase 2
Recruiting	`NCT03795610` - Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05814549` - A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
Recruiting	`NCT05307939` - A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)	Phase 2
Recruiting	`NCT05262010` - A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years	Phase 3
Recruiting	`NCT06157151` - PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer	Phase 2
Not yet recruiting	`NCT05976828` - IBRX-042 In Subjects With HPV-Associated Tumors	Phase 1
Not yet recruiting	`NCT05639972` - E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers	Phase 1/Phase 2
Not yet recruiting	`NCT06454175` - A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years	Phase 1
Not yet recruiting	`NCT06465914` - A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males	Phase 3
Active, not recruiting	`NCT03978689` - A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1
Recruiting	`NCT06305676` - Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)